Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as $12.58 and last traded at $12.7070, with a volume of 19242 shares trading hands. The stock had previously closed at $11.78.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pixclara (floretyrosine F 18, or 18F-FET), Telix’s amino-acid PET imaging agent for detecting and characterizing gliomas, a form of brain cancer. The approval covers imaging in both adults and children, creating a significant commercial opportunity in the U.S. and advancing Telix’s radiopharmaceutical pipeline. FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
• Positive Sentiment: Analysts at Wedbush reaffirmed an Outperform rating and set a $22 price target, signaling substantial potential upside from recent trading levels. The target provides additional investor confidence following the Pixclara approval. Wedbush rating coverage
• Neutral Sentiment: At the Morgan Stanley Global Healthcare Conference, Telix presented an overview of its business and development strategy. The event may improve visibility with institutional healthcare investors, although the supplied transcript does not identify a separate new financial forecast or material corporate announcement. Morgan Stanley Global Healthcare Conference Transcript

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Royal Bank Of Canada downgraded shares of Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research note on Friday, July 17th. Weiss Ratings raised shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research report on Friday, August 21st. Wedbush reaffirmed an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research report on Wednesday, September 2nd. Finally, Citigroup reissued a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $20.40.

Check Out Our Latest Research Report on TLX

Telix Pharmaceuticals Stock Up 8.5%

The business's fifty day moving average price is $11.22 and its 200 day moving average price is $10.20. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Lazard Asset Management LLC grew its holdings in shares of Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock worth $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals in the second quarter valued at approximately $1,731,000. Private Advisor Group LLC raised its position in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after acquiring an additional 128,070 shares during the last quarter. XY Capital Ltd lifted its stake in shares of Telix Pharmaceuticals by 468.0% in the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company's stock valued at $822,000 after purchasing an additional 58,739 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter.

Telix Pharmaceuticals Company Profile

(Get Free Report)

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

Further Reading

• Five stocks we like better than Telix Pharmaceuticals
• Navan's Strong Quarter Meets an AI Spending Reality Check
• LightPath’s Defense Pivot Could Send Shares Higher
• Clearance to Climb: Why Allegiant Has Room to Fly
• 3 Defense Stocks Riding the High-Energy Laser Boom

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Telix Pharmaceuticals Right Now?

Before you consider Telix Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.

While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here